Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
National Cancer Institute (NCI)
AstraZeneca
Genmab
Seagen Inc.
Mayo Clinic
STORM Therapeutics LTD
Neonc Technologies, Inc.
Ipsen
Bristol-Myers Squibb
Bayer
Pfizer
Radiopharm Theranostics, Ltd
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Aulos Bioscience, Inc.
Genentech, Inc.
OHSU Knight Cancer Institute
MacroGenics
DualityBio Inc.
MacroGenics
University of California, Davis
City of Hope Medical Center
Pfizer
ImmunityBio, Inc.
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
AbbVie
AgonOx, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Maastricht University Medical Center
Novartis
Pharmassist Ltd
Elephas
OncoNano Medicine, Inc.